Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Value Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Vanguard Value Index Fund ETF trades at $225. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals.
| REGN | VTV | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $227.51 |
52-Week Low | $555.51 | $182.86 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VTV, the Vanguard Value ETF, trades at $224.64, down 0.8% on the day, with technical indicators showing a neutral overall signal amid mixed moving average and oscillator readings. The fund's value-focused strategy has outperformed growth counterparts in 2026, attracting institutional inflows, though key financial ratios are not individually disclosed for the ETF. A dividend of $1.08 is scheduled for June 2026.
The outlook for VTV is supported by the ongoing rotation into value stocks, with media highlighting its 2026 strength versus growth ETFs. Risks include potential underperformance if growth resumes leadership and fee-related long-term tracking differences noted in analysis. The neutral technical stance suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
